BR112020003025A2 - métodos de tratamento de osteoartrite com gel transdérmico de canabidiol - Google Patents

métodos de tratamento de osteoartrite com gel transdérmico de canabidiol Download PDF

Info

Publication number
BR112020003025A2
BR112020003025A2 BR112020003025-2A BR112020003025A BR112020003025A2 BR 112020003025 A2 BR112020003025 A2 BR 112020003025A2 BR 112020003025 A BR112020003025 A BR 112020003025A BR 112020003025 A2 BR112020003025 A2 BR 112020003025A2
Authority
BR
Brazil
Prior art keywords
cbd
fact
cannabidiol
pain
patients
Prior art date
Application number
BR112020003025-2A
Other languages
English (en)
Portuguese (pt)
Inventor
John Messenheimer
Nancy Tich
Donna Gutterman
Daniel Clauw
Original Assignee
Zynerba Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zynerba Pharmaceuticals, Inc. filed Critical Zynerba Pharmaceuticals, Inc.
Publication of BR112020003025A2 publication Critical patent/BR112020003025A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BR112020003025-2A 2017-08-14 2018-08-13 métodos de tratamento de osteoartrite com gel transdérmico de canabidiol BR112020003025A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762545468P 2017-08-14 2017-08-14
US62/545,468 2017-08-14
US201862661733P 2018-04-24 2018-04-24
US62/661,733 2018-04-24
PCT/IB2018/056090 WO2019034985A1 (en) 2017-08-14 2018-08-13 METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL

Publications (1)

Publication Number Publication Date
BR112020003025A2 true BR112020003025A2 (pt) 2020-08-04

Family

ID=65362584

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020003025-2A BR112020003025A2 (pt) 2017-08-14 2018-08-13 métodos de tratamento de osteoartrite com gel transdérmico de canabidiol

Country Status (11)

Country Link
US (4) US20200170963A1 (https=)
EP (1) EP3668500A4 (https=)
JP (3) JP2020530857A (https=)
KR (1) KR20200054171A (https=)
AU (2) AU2018318425A1 (https=)
BR (1) BR112020003025A2 (https=)
CA (1) CA3072849A1 (https=)
IL (2) IL301622A (https=)
JO (1) JOP20200031A1 (https=)
MX (1) MX2020001768A (https=)
WO (1) WO2019034985A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
CA3300266A1 (en) 2017-09-28 2026-03-02 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
CA3122735A1 (en) 2018-12-14 2020-06-18 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
AU2020358869A1 (en) 2019-10-03 2022-04-14 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
EP4041210B1 (en) * 2019-10-13 2026-03-18 FibroBiologics, Inc. Combination of cannabidiol and fibroblasts for use in the treatment of disc degenerative disease
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
BR112022026044A2 (pt) * 2020-06-29 2023-03-07 Zynerba Pharmaceuticals Inc Tratamento de síndrome do x frágil com canabidiol
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
EP4098254A1 (en) * 2021-06-04 2022-12-07 Assistance Publique, Hopitaux De Paris Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
JP2025535174A (ja) * 2022-10-17 2025-10-22 インベンテージ ラボ インコーポレイテッド 炎症性疾患の治療または予防のための徐放型注射用組成物およびその製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
EP1890727B1 (en) * 2005-05-25 2012-10-03 CaloSyn Pharma, Inc Method and composition for treating osteoarthritis
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
CN102271705A (zh) * 2008-12-22 2011-12-07 墨尔本大学 骨关节炎治疗
CA2760460C (en) * 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
KR20150056522A (ko) * 2012-06-26 2015-05-26 앰버데일 엔터프라이지즈 피티와이 리미티드 초음파 공동화에 의한 지방 조직으로부터 줄기 세포의 분리 및 이의 이용 방법
EP3177286A4 (en) * 2014-07-18 2018-05-16 Medipath Inc. Compositions and methods for physiological delivery using cannabidiol
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法

Also Published As

Publication number Publication date
EP3668500A1 (en) 2020-06-24
IL272593A (en) 2020-03-31
JP2025024068A (ja) 2025-02-19
US20200170963A1 (en) 2020-06-04
JP2020530857A (ja) 2020-10-29
EP3668500A4 (en) 2021-04-28
IL301622A (en) 2023-05-01
US20250268843A1 (en) 2025-08-28
JP2023109969A (ja) 2023-08-08
CA3072849A1 (en) 2019-02-21
US20240189255A1 (en) 2024-06-13
MX2020001768A (es) 2020-12-03
JOP20200031A1 (ar) 2020-02-12
KR20200054171A (ko) 2020-05-19
AU2018318425A1 (en) 2020-02-27
JP7590803B2 (ja) 2024-11-27
AU2024205778A1 (en) 2024-09-05
WO2019034985A1 (en) 2019-02-21
US20240148669A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
BR112020003025A2 (pt) métodos de tratamento de osteoartrite com gel transdérmico de canabidiol
JP6673924B2 (ja) 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール
CN101198362A (zh) 在癌症化疗和放疗时保护细胞的局部血管收缩剂制品和方法
BR112020004947A2 (pt) canabidiol transdérmico sintético para o tratamento de epilepsia focal em adultos
Scheinfeld Topical treatments of skin pain: a general review with a focus on hidradenitis suppurativa with topical agents
WO2016044131A1 (en) Method of treating prader-willi syndrome
JP2022519721A (ja) 睡眠時無呼吸を治療するための方法および組成物
Joppich et al. Analgesic efficacy and tolerability of intravenous morphine versus combined intravenous morphine and oxycodone in a 2-center, randomized, double-blind, pilot trial of patients with moderate to severe pain after total hip replacement
Aydın et al. Pain prevention with intraoperative ketamine in outpatient children undergoing tonsillectomy or tonsillectomy and adenotomy
JP2022546456A (ja) 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
RU2616520C2 (ru) Лечение симптомов, связанных с гастропарезом у женщин
ES2447829T3 (es) Combinación para el tratamiento de la osteoartritis
Joseph et al. Efinaconazole 10% solution in the treatment of onychomycosis of the toenails
WO2021205402A1 (en) Endoxifen for the treatment of bipolar i disorder
Tankl et al. To evaluate role of gabapentin as a preemptive analgesic in the patients undergoing modified radical mastectomy
Fang et al. Phase 1 single-centre, placebo and levobupivacaine controlled study in healthy volunteers to assess the safety, tolerability, efficacy, and pharmacokinetics of LL10, a novel long-acting local anaesthetic
JP5376481B1 (ja) 経皮吸収用医薬組成物
IL230174A (en) Pharmaceutical composition for the treatment of premature ejaculation
Khokar et al. Oral versus intravenous paracetamol for perioperative analgesia in patients undergoing total abdominal hysterectomy-A randomised double-blind controlled trial
Kolling et al. The use of extemporaneously compounded 1% tetracaine to improve adherence with clotrimazole 1% topical solution in the treatment of ear infection: A case report
Sigg et al. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium-and long-term efficacy and safety of topical rapamycin
TW202440106A (zh) 用於治療勃起障礙之化合物
Soroka et al. Ketamine in affective disorders–expectations and limitations
Ongzalima et al. The Foot and Ankle Online Journal
JPWO2019135363A1 (ja) 腱滑膜病変を主体とした疾患の治療薬

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HARMONY BIOSCIENCES MANAGEMENT, INC. (US)

B25G Requested change of headquarter approved

Owner name: HARMONY BIOSCIENCES MANAGEMENT, INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]